Loading
A phase 3 trial of Cisplatin, Cyclophosphamide, Lomustine, Sodium thiosulfate and Vincristine in Medulloblastoma, run by Children's Oncology Group, now recruiting.
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss is a phase 3 interventional study registered as NCT05382338 by Children's Oncology Group, with 225 participants planned, started 2023-02-20 and due to reach its primary completion in 2029-12-31. Interventions recorded: Audiometric Test, Auditory Brainstem Response, Biospecimen Collection, Cisplatin, Cyclophosphamide, Lomustine, Magnetic Resonance Imaging, Quality-of-Life Assessment, Radiation Therapy, Sodium Thiosulfate, Survey Administration, Vincristine. Conditions recorded: Childhood Medulloblastoma.
Linked to the drug Sodium thiosulfate because the registry names it among its interventions and Medulloblastoma among its conditions. Registry record only: no result has been read by an editor.
Shares Sodium thiosulfate (otoprotectant), Cisplatin and the tag pipeline.
Shares Sodium thiosulfate (otoprotectant), Children's Oncology Group (COG) and the tag pipeline.
Shares Lomustine (CCNU) and the tag pipeline.
Shares Children's Oncology Group (COG), Vincristine, Cyclophosphamide and the tag pipeline.
Shares Vincristine, Cyclophosphamide and the tag pipeline.
Shares Vincristine, Cyclophosphamide and the tag pipeline.
Shares Children's Oncology Group (COG), Vincristine, Cyclophosphamide and the tag pipeline.
Shares Vincristine, Cyclophosphamide and the tag pipeline.